26 May 2013
Keywords: enrollment, complete, ph, ii/iii, duocort, trial, helsingborg
Article | 17 December 2007
Helsingborg, Sweden-based DuoCort Pharma AB says that targeted enrollment is complete in a pivotal Phase II/III trial evaluating 5mg
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
17 December 2007
24 May 2013
© 2013 thepharmaletter.com